These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35038762)

  • 21. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
    Bench AJ; White HE; Foroni L; Godfrey AL; Gerrard G; Akiki S; Awan A; Carter I; Goday-Fernandez A; Langabeer SE; Clench T; Clark J; Evans PA; Grimwade D; Schuh A; McMullin MF; Green AR; Harrison CN; Cross NC;
    Br J Haematol; 2013 Jan; 160(1):25-34. PubMed ID: 23057517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
    Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
    Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aquagenic pruritus and the JAK2 V617F mutation.
    Langabeer SE
    Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombotic incidents in patients with myelofibrosis suggest to be independent of
    Nikolova D; Radinov A
    Folia Med (Plovdiv); 2022 Aug; 64(4):655-660. PubMed ID: 36045460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
    Mishima E; Suzuki T; Takeuchi Y; Seiji K; Fukuhara N; Takase K; Harigae H; Abe T; Ito S
    J Clin Hypertens (Greenwich); 2018 Apr; 20(4):798-804. PubMed ID: 29656438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
    Ali FR; Roberts LN; Mistry H; Patel RK; Edmondson RA; Arya R
    J Vasc Surg; 2009 Jan; 49(1):211-3. PubMed ID: 19174256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
    Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
    Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
    [No Abstract]   [Full Text] [Related]  

  • 30. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
    Girsberger S; Karow A; Lundberg P; Dirnhofer S; Lehmann T; Passweg JR; Tichelli A; Skoda R; Rovó A
    Acta Haematol; 2013; 129(1):23-5. PubMed ID: 23006959
    [No Abstract]   [Full Text] [Related]  

  • 31. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid neoplasms with isolated del(5q) and
    Sangiorgio VFI; Geyer JT; Margolskee E; Al-Kawaaz M; Mathew S; Tam W; Orazi A
    Haematologica; 2020 Jun; 105(6):e276-e279. PubMed ID: 31558664
    [No Abstract]   [Full Text] [Related]  

  • 33. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms.
    Elf SE
    Haematologica; 2021 Jul; 106(7):1783-1784. PubMed ID: 33567815
    [No Abstract]   [Full Text] [Related]  

  • 35. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation.
    Chan KL; McKelvie P; Firkin F; Bazargan A; Tam CS
    Leuk Lymphoma; 2013 May; 54(5):1110-2. PubMed ID: 23088192
    [No Abstract]   [Full Text] [Related]  

  • 38. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
    Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The JAK2 V617F mutation in pediatric myeloproliferative neoplasms: how and when?
    Langabeer SE; Smith OP; McMahon C
    Pediatr Hematol Oncol; 2014 Mar; 31(2):138-9. PubMed ID: 24383477
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.